RegulatoryCompany release

FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer

Roche · Mon 16 Nov 2026

Roche says the US regulator cleared giredestrant plus everolimus after prior endocrine therapy, with a separate adjuvant application due a decision on 30 November 2026.

Roche announced on 16 November 2026 that the US Food and Drug Administration has approved Wilserdly (giredestrant), an oral selective oestrogen receptor degrader (SERD), in combination with everolimus. The indication covers adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have previously received endocrine therapy.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Roche ↗

Article written by VigiEye from the official source (Roche). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →